USAID awards $5 million to CONRAD

November 02, 2010

Arlington, VA - November 2, 2010 - CONRAD, leaders in reproductive health and HIV prevention research, today announced a $5 million award from the US Agency for International Development (USAID). The grant will fund research and development of vaginal rings that are contraceptive and also prevent HIV and STI infections.

USAID provided funding for the CAPRISA 004 trial of tenofovir gel, conducted by the Centre for Programme Research for AIDS in South Africa (CAPRISA), which was the first study to show that a vaginal gel can reduce the risk of HIV and herpes infection in women. CONRAD manufactured and provided the tenofovir gel for the study. Tenofovir gel was found to be 39% effective in reducing a woman's risk of becoming infected with HIV during sex and 51% effective in preventing genital herpes infections in the women participating in the trial. The FDA recently granted Fast Track approval designation for tenofovir gel, pending confirmatory results from the NIH-sponsored Phase IIB study, MTN-003, known as VOICE (Vaginal and Oral Interventions to Control the Epidemic.) CONRAD's pre-clinical and product development team are evaluating products that include combination gels and barrier methods, such as an intravaginal ring impregnated with tenofovir and a contraceptive that is the subject of this grant.

"Thanks to USAID, we have been able to manufacture the first product to reduce women's risk of HIV and herpes," said Henry Gabelnick, Executive Director of CONRAD. "This award will allow us to expedite the evaluation of a dual-protection technology that promises to be a breakthrough in the simultaneous prevention of unplanned pregnancies and HIV infection."

Almost half of all pregnancies worldwide, estimated to be over 100 million annually, are unintended. In sub-Saharan Africa in particular, low contraceptive use rates are reflected by high fertility rates, and thus high infant and maternal mortality rates. This area of the world is also the core of the AIDS epidemic, with 22.4 million people infected with HIV, many of them young women. Poverty, malnutrition, lack of education and gender inequality fuel both unintended pregnancies and HIV transmission; therefore, there is an urgent need to develop dual protection technologies.

"We strongly support research that focuses on women's health in developing countries and a dual-protection product that can prevent unintended pregnancies as well as HIV and other STIs can make an enormous difference," said Dr. Judy Manning with USAID. "CONRAD has been on the forefront of this technology and we are proud to support their work."
-end-
CONRAD is a cooperating agency of USAID committed to improving reproductive health by expanding the contraceptive choices of women and men and by helping to prevent the transmission of HIV/AIDS and other sexually transmitted diseases. CONRAD is a Division of the Department of Obstetrics and Gynecology at Eastern Virginia Medical School (EVMS) in Norfolk, VA, where it has laboratories and a clinical research center. The main office is located in Arlington, VA with an additional office in West Chester, PA. For more information, go to www.conrad.org.

CONRAD

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.